189 related articles for article (PubMed ID: 15534130)
21. A randomized, 36-month, post-marketing efficacy and tolerability study in Sweden and Finland of latanoprost versus non-prostaglandin therapy in patients with glaucoma or ocular hypertension.
Friström B; Uusitalo H
Acta Ophthalmol; 2010 Feb; 88(1):37-43. PubMed ID: 19900212
[TBL] [Abstract][Full Text] [Related]
22. Mechanism and clinical significance of prostaglandin-induced iris pigmentation.
Stjernschantz JW; Albert DM; Hu DN; Drago F; Wistrand PJ
Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S162-75. PubMed ID: 12204714
[TBL] [Abstract][Full Text] [Related]
23. Latanoprost stimulates eumelanogenesis in iridial melanocytes of cynomolgus monkeys.
Prota G; Vincensi MR; Napolitano A; Selen G; Stjernschantz J
Pigment Cell Res; 2000 Jun; 13(3):147-50. PubMed ID: 10885672
[TBL] [Abstract][Full Text] [Related]
24. Incidence of iris colour change in latanoprost treated eyes.
Teus MA; Arranz-Márquez E; Lucea-Suescun P
Br J Ophthalmol; 2002 Oct; 86(10):1085-8. PubMed ID: 12234883
[TBL] [Abstract][Full Text] [Related]
25. Comparison of iridial pigmentation between latanoprost and isopropyl unoprostone: a long term prospective comparative study.
Chiba T; Kashiwagi K; Chiba N; Ishijima K; Furuichi M; Kogure S; Abe K; Tsukahara S
Br J Ophthalmol; 2003 Aug; 87(8):956-9. PubMed ID: 12881333
[TBL] [Abstract][Full Text] [Related]
26. Timolol + latanoprost: new preparation. Last-resort eye drops.
Prescrire Int; 2003 Oct; 12(67):173-4. PubMed ID: 14619889
[TBL] [Abstract][Full Text] [Related]
27. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma.
Mastropasqua L; Carpineto P; Ciancaglini M; Gallenga PE
Ophthalmology; 1999 Mar; 106(3):550-5. PubMed ID: 10080213
[TBL] [Abstract][Full Text] [Related]
28. alpha-Methyl-p-tyrosine inhibits latanoprost-induced melanogenesis in vitro.
Drago F; Marino A; La Manna C
Exp Eye Res; 1999 Jan; 68(1):85-90. PubMed ID: 9986745
[TBL] [Abstract][Full Text] [Related]
29. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
[TBL] [Abstract][Full Text] [Related]
30. The color of the human eye: a review of morphologic correlates and of some conditions that affect iridial pigmentation.
Imesch PD; Wallow IH; Albert DM
Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S117-23. PubMed ID: 9154287
[TBL] [Abstract][Full Text] [Related]
31. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
[TBL] [Abstract][Full Text] [Related]
32. 24-hour efficacy of the bimatoprost-timolol fixed combination versus latanoprost as first choice therapy in subjects with high-pressure exfoliation syndrome and glaucoma.
Konstas AG; Holló G; Mikropoulos DG; Haidich AB; Dimopoulos AT; Empeslidis T; Teus MA; Ritch R
Br J Ophthalmol; 2013 Jul; 97(7):857-61. PubMed ID: 23686322
[TBL] [Abstract][Full Text] [Related]
33. [Relative contraindication of latanoprost in iris tumors with secondary glaucoma].
Fröhlich SJ; Mueller AJ; Kampik A
Ophthalmologe; 2003 Aug; 100(8):633-8. PubMed ID: 12955445
[TBL] [Abstract][Full Text] [Related]
34. Effect of age on the development of a latanoprost-induced increase in iris pigmentation.
Arranz-Marquez E; Teus MA
Ophthalmology; 2007 Jul; 114(7):1255-8. PubMed ID: 17306877
[TBL] [Abstract][Full Text] [Related]
35. Prostaglandins: a new approach to glaucoma management with a new, intriguing side effect.
Bito LZ
Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S1-14. PubMed ID: 9154271
[TBL] [Abstract][Full Text] [Related]
36. Incidence and severity of iris pigmentation on latanoprost-treated glaucoma eyes.
Chou SY; Chou CK; Kuang TM; Hsu WM
Eye (Lond); 2005 Jul; 19(7):784-7. PubMed ID: 15359238
[TBL] [Abstract][Full Text] [Related]
37. Production of prostaglandin e(2) by iridial melanocytes exposed to latanoprost acid, a prostaglandin F(2 alpha) analogue.
Bergh K; Wentzel P; Stjernschantz J
J Ocul Pharmacol Ther; 2002 Oct; 18(5):391-400. PubMed ID: 12419090
[TBL] [Abstract][Full Text] [Related]
38. Impact of age, diagnosis, and history of glaucoma surgery on outcomes in pediatric patients treated with latanoprost.
Maeda-Chubachi T; Chi-Burris K; Simons B; Brémond-Gignac D; Freedman S; Khaw PT; Wirostko B; Yan E;
J Glaucoma; 2013; 22(8):614-9. PubMed ID: 23524858
[TBL] [Abstract][Full Text] [Related]
39. Severe darkening of a facial skin graft from latanoprost.
Calladine D; Harrison RJ
Arch Ophthalmol; 2007 Oct; 125(10):1427-8. PubMed ID: 17923558
[No Abstract] [Full Text] [Related]
40. Evidence of early change in iris color with latanoprost use.
Pappas RM; Pusin S; Higginbotham EJ
Arch Ophthalmol; 1998 Aug; 116(8):1115-6. PubMed ID: 9715697
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
